🇺🇸 FDA
Pipeline program

Teniposide administration

VM26-201

Phase 2 small_molecule active

Quick answer

Teniposide administration for Extensive-stage Small Cell Lung Cancer (ES-SCLC) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials